Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Analysis of the Prognostic Value of Immune Checkpoints in Gastric Adenocarcinoma
Read More
PANTHERA: Triplet Pembrolizumab, Trastuzumab, and Chemotherapy First-Line Therapy Is Effective in HER2-Positive Advanced Gastric/GEJ Cancer Regardless of PD-L1 Status
Read More
ATTRACTION-2: Nivolumab Conveys Survival Benefit for Patients with Advanced Gastric/GEJ Cancer When Used as Treatment Beyond Progression
Read More
KEYNOTE-181: Improved OS in Patients with Advanced Esophageal Cancer Treated with Second-Line Pembrolizumab
Read More
ASCO Releases Clinical Guidelines for the Treatment of Patients with Advanced Esophageal Cancer
Read More
DELIVER: Real-World Data Analysis of Nivolumab Monotherapy in Advanced Gastric Cancer
Read More
CALGB 80803: PET-Directed Therapy After Induction Chemotherapy Yields Promising 5-Year Overall Survival in Patients with Esophageal Cancer
Read More
Sintilimab with CapeOx Demonstrates Promising Efficacy and Manageable Safety Profile as Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric/GEJ Cancer
Read More
MAHOGANY: Margetuximab and Retifanlimab Combination Is Well-Tolerated in Patients with HER2-Positive, PD-L1–Positive, Metastatic Gastroesophageal Adenocarcinoma
Read More
CIRCUIT: Nivolumab Combined with Radiotherapy in Patients with Advanced Gastric Cancer Yields Promising Responses
Read More
78
79
80
81
82
83
84
Page 81 of 199
Results 801 - 810 of 1986
